Cellular Biomedicine Group Inc., of Shanghai, said it received a $30.6 million investment from Sailing Capital Overseas Investment Ltd. and its affiliates, a global private equity firm focused on China cross-border investments. The company said it has demonstrated clinical proof of concept of a CAR T-cell immuno-oncology platform and the current investment will enable its further clinical development.